A phase II dose evaluation pilot feasibility randomized controlled trial of cholecalciferol in critically ill children with vitamin D deficiency (VITdAL-PICU study)

Table 2 Number of patients by treatment arm with a plasma 25(OH)D concentration above 75, 200 and 250 nmol/L

	N	Treatment (n = 38)	Placebo (n = 18)
Clinical Sample + Imputed Sample, plasma 25(OH)D concentration (nmol./L)^a	56	118.4 (91.0, 146.3)	43.0 (35.5, 53.0)
Clinical Sample + Imputed Sample,frequency (%)^a
> 75 nmol/L	56	31 (81.6)	1 (5.6)
> 200 nmol/L	56	4 (10.5)	0 (0.0)
> 250 nmol/L	56	2 (5.3)	0 (0.0)
	N	Treatment (n = 30)	Placebo (n = 14)
Clinical Sample Only plasma 25(OH)D concentration (nmol./L)^b	44	118.0 (94.2, 146.1)	43.0 (36.0, 54.5)
Clinical Sample Only,frequency (%)^b
> 75 nmol/L	44	25 (83.3)	1 (7.1)
> 200 nmol/L	44	3 (10.0)	0 (0.0)
> 250 nmol/L	44	1 (3.3)	0 (0.0)

^aBased on Clinical Sample with imputed results for missing blood samples (primary outcome data)
^bBased on Clinical Sample only (no imputed results)
25(OH)D – 25-hydroxyvitamin D

ISSN: 1471-2431